FDA Approves Frontline Gazyva (obinutuzumab) for CLL

Share this content:

The FDA has approved Gazyva (obinutuzumab; Genentech) for use in combination with chlorambucil to treat patients with previously untreated chronic lymphocytic leukemia (CLL).

Obinutuzumab (GA101) is the first type II anti-CD20 medicine that is glycoengineered, which creates a unique antibody designed to act as an immunotherapy, engaging the patient's own immune system to help attack the cancerous cells. In addition, GA101 binds to CD20 with the aim of inducing direct cell death.

Related: Hematologic Cancers Resource Center

The approval is based on the findings of the Phase 3 CLL11 trial. The study showed that patients who received Gazyva in combination with chlorambucil chemotherapy had significantly reduced risk of disease progression or death (HR=0.16; P<0.0001) and lived significantly longer without their disease getting worse compared to those who received chlorambucil alone (median PFS 23.0 months vs. 11.1 months).

Gazyva was granted Breakthrough Therapy designation due to the significance of the positive results from its Phase 3 CLL 11 trial and the serious and life-threatening nature of CLL.

Gazyva will be available in a 1000mg/40mL (25mg/mL) strength as a single-use vial in approximately two weeks.

For more information call (800) 821-8590 or visit Gazyva.com.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs